Drugs / XZP-6019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05063968 | Nov 2021 → Sep 2022 | NAFLD1 | Xuanzhu Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XZP-6019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05063968 ↗ |
| Route | Oral | “Tablet is administered orally once on Day 1 and Day 9, respectively” NCT05063968 ↗ |